Trial intelligence / Profile preview

Aprepitant in geriatric major depressive disorder

NCT00035048Phase 3Completed

Sponsor: Merck & Co.
Start: Nov 2001
Primary completion: Dec 2003

Overview

Phase 3, randomised, double-blind trial in major depressive disorder (MDD) comparing aprepitant with placebo (2 arms). Primary endpoints: Hamilton Depression Rating Scale at 10 months, Maintenance of antidepressant effect at 10 months and 1 more. Started Nov 2001; status: completed.

Drugs

aprepitant

Conditions

major depressive disorder (MDD)

Beyond the preview

Go deeper on NCT00035048.

Study design, results and competitive context are available in the Gosset platform where reported.

Study design & results

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on NCT00035048.